Ayuko Nakano, Y. Hattori, Chie Aoki
Jul 10, 2009
Citations
1
Influential Citations
35
Citations
Quality indicators
Journal
Hypertension Research
Abstract
Telmisartan is an angiotensin-II type 1 receptor (AT1R) blocker, currently used to treat patients with hypertension. Telmisartan, in addition to its effect on AT1R, is thought to activate the nuclear transcription factor, peroxisome proliferator-activated receptor-γ (PPAR γ), thereby acting as a partial PPARγ agonist. This study was conducted to examine whether telmisartan might suppress cytokine-induced inflammatory signaling in vascular endothelial cells, thereby attenuating cellular inflammation possibly by PPARγ activation. Telmisartan caused a dose-dependent suppression of the tumor necrosis factor-α (TNFα)-induced activation of nuclear factor (NF)-κB in vascular endothelial cells in this study. The PPARγ antagonist, GW9662, did not influence the inhibitory effect of telmisartan on NF-κB activation. The thiazolidinediones neither influenced TNFα-induced NF-κB activation nor influenced the inhibitory effect of telmisartan in this process. Telmisartan dose dependently diminished the TNFα-induced gene expression of VCAM-1, and GW9662 did not attenuate this effect. Thus, telmisartan inhibits the cytokine-induced expression of the VCAM-1 gene by blocking NF-κB activation independently of PPARγ activation. Although the mechanism by which this occurs remains unclear, our findings suggest that telmisartan-induced anti-inflammatory effects might have favorable effects on vasculature in hypertensive patients.